Superdisintegrants Market Size to Grow USD 1,025.45 Million by 2035

Segmental Insights

Form Insights

How the Tablets and Capsules Segment Dominated the Superdisintegrants Market?

The tablets and capsules segment accounted for the highest revenue share of the market in 2025, due to their established role in immediate-release and controlled-release oral therapy regimens widely prescribed across global healthcare systems.

These dosage forms frequently incorporate superdisintegrants to ensure consistent disintegration and rapid drug availability in conventional and generics portfolios. Moreover, the use of tablets and capsules orally in chronic and acute therapeutic settings is expected to facilitate the adoption of tested and proven dosages of tablets and capsules in the coming years.

The mouth-dissolving films (MDFs) segment is expected to grow with the highest CAGR in the market during the studied years, owing to the increasing patient preference for convenient and swallow-friendly dosage forms, particularly among elderly and pediatric populations with swallowing impairments. The development of hot melt extrusion and solvent casting processes helps produce MDFs with high efficiency in terms of uniform thickness and the ability to disperse.
New combinations of excipients enabling flexible loading of active moieties into film matrices were the focus of industry conferences and symposia. Furthermore, the growing demand for patient-centric therapies and expanded R&D focus on sensory acceptable, quick action formats, potentiating the demand for MDFs.

Regional Insights

Why North America Dominated the Superdisintegrants Market?

North America led the market in 2025, as it has the most developed pharma manufacturing systems and a long-term focus on the development of high-quality solid oral dosage, owing to the elaborate quality standards enforced by the U.S. FDA and pharmacy standards in accordance with the USP quality standards. The formulators focus on consistent excipient performance of tablets and capsules.

The FDA launched initiatives in 2025 to boost domestic drug production, including a pilot program and the FDA PreCheck scheme to expedite review and construction of manufacturing facilities, strengthening local production capabilities and encouraging investments in formulation science. Moreover, the leadership in regulatory compliance and advanced formulation practices continues to secure North America’s position as a core regional base for excipient utilization.

U.S. – Leading North America’s Pharmaceutical Strength

The U.S. leads the market in North America due to its advanced regulatory ecosystem and significant drug production scope. In 2026, regional programs such as the FDA PreCheck and the EO 14293 on onshoring pharmaceuticals support the growth of local production and supply chain resiliency. This makes it easier to integrate technologies in excipient tablet production. Furthermore, continued investments in research and development infrastructure and formulation science have ensured that U.S. drug manufacturers remain in the lead to create complex oral solid dosage forms.

Why is Asia-Pacific Projected to Grow Fastest in the Superdisintegrants Market?

Asia-Pacific is expected to witness the fastest growth during the predicted timeframe, owing to the expanding pharmaceutical production capacity, regulatory improvements, and increasing integration into global supply chains across China, India, South Korea, and Southeast Asia. In 2025, the National Medical Products Administration (NMPA) of China introduced specific GMP annexes of pharmaceutical excipients and packaging materials.

This improves quality control and aligns the local needs with the global practice, which is expected to further raise the level of excipient manufacturing. Oxford Economics projects continued percentage gains in overall production, which supports broader formulation and excipient demand. Additionally, government incentives and policies that support pharmaceutical exports and quality improvements are likely to fuel the market in this region.

India – Driving Growth in Asia Pacific’s Pharmaceutical Landscape

China is leading the charge in the Asia-Pacific market, supported by expansive generic drug manufacturing and deep global integration. Pharma exports in India increased to USD 30.5 billion in FY25 as a result of the increasing international demand. This further supports other related excipient segments applied in solid formulations. Furthermore, India’s strategic position in the global pharmaceutical value chain is projected to sustain strong momentum for oral dosage technologies and underpin regional growth.

Superdisintegrants Market Value Chain Analysis

• Raw Material Sourcing
  Procurement of cellulose, starches, and polymer precursors forms the foundation of superdisintegrant production.
  Key Players: Wood pulp suppliers, cellulose producers, starch manufacturers
• Chemical Synthesis & Intermediate Production
  Raw materials are chemically modified to produce intermediates with excipient functionality.
  Key Players: Polymer chemical manufacturers, excipient intermediates processors

Superdisintegrants Market Companies

• Asahi Kasei Corporation
• Ashland
• BASF SE
• Corel Pharma Chem.
• DFE Pharma
• DuPont.
• JRS PHARMA
• Merck KGaA
• NIPPON SODA CO., LTD.
• Roquette Frères.

Recent Developments in the Superdisintegrants Market

• In February 2026, DFE Pharma introduced its Continuous Manufacturing (CM) platform to support pharmaceutical companies in formulation development, optimization, and lifecycle management of CM processes. Developed in collaboration with Gericke, the platform combines CM-ready excipients, an evaluation environment, and multidisciplinary expertise, enabling data-driven decisions from early development through long-term CM operations.(Source: https://www.expresspharma.in)
• In February 2026, Lupin Limited signed a licensing and supply agreement with Spektus Pharma to commercialize the novel antidepressant DeslaFlex in Canada. Utilizing Spektus’s proprietary Flexitab oral drug-delivery platform, the partnership combines Lupin’s strong Canadian commercial footprint with Spektus’s expertise in differentiated formulations.(Source: https://www.lupin.com)
• In October 2025, Asahi Kasei announced the launch of two new specialty grades in its Sonanos excipient portfolio. These next-generation excipients, designed to improve injectable drug formulations, are manufactured under GMP standards, with commercial availability expected in 2027. (Source: https://www.contractpharma.com)
• In September 2025, Eli Lilly and Company announced plans to construct a USD 6.5 billion next-generation manufacturing facility at Generation Park in Houston, Texas. This facility, the second of four new U.S. sites planned for 2025, will focus on producing small-molecule APIs across therapeutic areas such as cardiometabolic health, oncology, immunology, and neuroscience.(Source:https://www.prnewswire.com)

Segments Covered in the Report

By Product

• Croscarmellose sodium
• Crospovidone
• Ion Exchange Resin
• Sodium Starch Glycolate
• Others

By Form

• Tablets and Capsules
• Mouth-dissolving Films

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

Check this report to:https://www.marketstatsinsight.com/icu-ecg-patient-monitor-market-size/

For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com